Do vasoactive medications impact donor hearts clinical outcomes in pediatric heart transplantation?
Pediatric Transplantation · 2023
DOI: 10.1111/petr.14500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2023. Verfasst von David Blitzer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Cardiovascular Surgery, Columbia University, New York, New York, USA. Hauptthemen laut MEDLINE: Heart Transplantation, Tissue and Organ Procurement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Objectives
There is limited data examining donor vasopressor and/or inotrope medications (vasoactives) on pediatric orthotopic heart transplant (OHT) outcomes. We aim to evaluate the effects of vasoactives on pediatric OHT outcomes.
Methods
The United Network for Organ Sharing database was retrospectively reviewed from January 2000 to March 2018 for donor hearts. Exclusion criteria included multiorgan transplants and recipient age >18. Donors receiving vasoactives at the time of procurement were compared to donors not on vasoactives, including the number of vasoactives and the type. End‐points of interest were survival at 30 days and 1 year as well as post‐transplant rejection at 1 year. Logistic and Cox models were used to quantify survival end‐points.
Results
Of 6462 donors, 3187 (49.3%) were receiving at least one vasoactive. Comparing any vasoactive medication versus none, there was no difference in 30‐day survival ( p = .27), 1 year survival ( p = .89), overall survival ( p = .68), or post‐transplant rejection ( p = .98). There was no difference in 30‐day survival for donors receiving 2 or more vasoactive infusions ( p = .89), 1 year survival ( p = .53), overall survival ( p = .75), or post‐transplant rejection at 1 year ( p = .87). Vasopressin was associated with decreased 30‐day mortality (OR = 0.22; p = .028), dobutamine with decreased 1‐year mortality (OR = 0.37; p = .036), overall survival (HR = 0.51; p = .003), and decreased post‐transplant rejection (HR = 0.63; p = .012).
Conclusions
There is no difference in pediatric OHT outcomes when the cardiac donor is treated with vasoactive infusions at procurement. Vasopressin and dobutamine were associated with improved outcomes. This information can be used to guide medical management and donor selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Division of Cardiovascular Surgery, Columbia University, New York, New York, USA.
- Fulcrum, Jackson, Mississippi, USA.
- Division of Cardiothoracic Surgery, TransMedics, Inc., Andover, Massachusetts, USA.
- Department of Surgery, University of Arizona, Tucson, Arizona, USA.
- Cleveland Clinic Heart Vascular and Thoracic Institute, Weston, Florida, USA.
- Lutheran Hospital, Fort Wayne, Indiana, USA.
ORCID-Profile: David Blitzer, Hannah Copeland
Zitieren
APA
Blitzer, D., Lirette, S., Kane, L., Copeland, J. G., Baran, D. A., & Copeland, H. (2023). Do vasoactive medications impact donor hearts clinical outcomes in pediatric heart transplantation?. Pediatric Transplantation. https://doi.org/10.1111/petr.14500
Vancouver
Blitzer D, Lirette S, Kane L, Copeland JG, Baran DA, Copeland H. Do vasoactive medications impact donor hearts clinical outcomes in pediatric heart transplantation?. Pediatric Transplantation. 2023. doi:10.1111/petr.14500
BibTeX
@article{Blitzer2023,
author = {Blitzer, David and Lirette, Seth and Kane, Lauren and Copeland, Jack G and Baran, David A and Copeland, Hannah},
title = {Do vasoactive medications impact donor hearts clinical outcomes in pediatric heart transplantation?},
journal = {Pediatric Transplantation},
year = {2023},
doi = {10.1111/petr.14500}
}
EUVIMED